Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab

MeSH terms

• Antirheumatic Agents / administration & dosage
• Antirheumatic Agents / adverse effects
• Antirheumatic Agents / immunology
• Betacoronavirus / isolation & purification
• COVID-19
• COVID-19 Testing
• Clinical Laboratory Techniques / methods
• Comorbidity
• Coronavirus Infections* / diagnosis
• Coronavirus Infections* / epidemiology
• Coronavirus Infections* / physiopathology
• Coronavirus Infections* / therapy
• Granulomatosis with Polyangiitis* / drug therapy
• Granulomatosis with Polyangiitis* / epidemiology
• Granulomatosis with Polyangiitis* / immunology
• Humans
• Immunocompromised Host
• Male
• Middle Aged
• Monitoring, Immunologic / methods
• Pandemics*
• Patient Acuity
• Patient Care Management / methods
• Peroxidase / immunology
• Pneumonia, Viral* / diagnosis
• Pneumonia, Viral* / epidemiology
• Pneumonia, Viral* / physiopathology
• Pneumonia, Viral* / therapy
• Recurrence
• Rituximab* / administration & dosage
• Rituximab* / adverse effects
• Rituximab* / immunology
• SARS-CoV-2
• Symptom Assessment / methods
• Treatment Outcome